Figure 3

Hepatitis C virus (HCV) prevalence among populations at indirect or intermediate risk and special clinical populations in Egypt, in studies conducted pre and post the 2001. A: Graph depicting HCV prevalence among different populations at indirect or intermediate risk in Egypt. B: Graph depicting HCV prevalence among different special clinical populations¹ in Egypt. In this figure, we included only stratified HCV prevalence measures, if these stratified measures were available. Otherwise, we included the overall prevalence measures in the study. ¹Acronyms: BC: bladder cancer, CLD: chronic liver disease, CRF: chronic renal failure, CV: cutaneous vasculitis, GIB: gastrointestinal bleeding, GN: glomerulonephritis, HCC: hepatocellular carcinoma, HCCA:hilarcholangiocarcinoma, HL: Hodgkin’s lymphoma, KTP: kidney transplant patients, LD: liver diseae, LP:lichen planus, MDS: myelodysplastic syndrome NHL: non-Hodgkin’s lymphoma, RHD: rheumatic heart disease, SLE: systematic lupus erthymatosus.